It also said GSK continued to sell and promote the drug despite knowing the increased risk of heart attacks and stroke.The Senate Finance Committee, in a panel investigation, revealed emails from GSK company officials that suggest the company downplayed scientific findings about safety risks dating back to 2000. It was also alleged by the committee that the company initiated a "ghostwriting campaign", whereby GSK sought outside companies to write positive articles about Avandia to submit to medical journals. GSK defended itself by presenting data that its own tests found Avandia to be safe, although an FDA staff report showed the conclusions were flawed.On July 14, 2010, after two days of extensive deliberations, the FDA panel investigating Avandia came to a mixed vote. Twelve members of the panel voted to take the drug off the market, 17 recommended to leave it on but with a more revised warning label, and three voted to keep it on the market with the current warning label. The panel has come to some controversy, however; on July 20, 2010, one of the panelists was discovered to have been a paid speaker for GlaxoSmithKline, arousing questions of a conflict of interest. This panel member was one of the three who voted to keep Avandia on the market with no additional warning labels.In 2011 the FDA has decided on revising its prescribing information and medication guides for all rosilitazone containing medicines. The US label for rosiglitazone (Avandia, GlaxoSmithKline) and all rosiglitazone-containing medications (Avandamet and Avandaryl) now include the additional safety information and restrictions.
The involvement of the immune system in this putative condition has also been theorized but has never been proven.Purported symptoms of metallosis generally include pain around the site of the implant, pseudotumors (a mass of inflamed cells that resembles a tumor but is actually collected fluids), and a noticeable rash that indicates necrosis. The damaged and inflamed tissue can also contribute to loosening the implant or medical device. Metallosis can cause dislocation of non-cemented implants as the healthy tissue that would normally hold the implant in place is weakened or destroyed. Metallosis has been demonstrated to cause osteolysis.Women, those who are small in stature, and the obese are at greater risk for metallosis because their body structure causes more tension on the implant, quickening the abrasion of the metal components and the subsequent build-up of metallic debris. Physical effects and symptoms
Persons suffering from metallosis can experience any of the following symptoms:

Extreme pain (even when not moving);
Swelling and inflammation;
Loosening of the implant;
Joint dislocation;
Bone deterioration;
Aseptic fibrosis, local necrosis;
Hip replacement failure;
Metal toxicity from grinding metal components; and
Necessary subsequent hip replacement revision or surgeries. Complications
As the grinding components cause metal flakes to shed from the system, the implant wears down. Metallosis results in numerous additional side effects:

Confusion;
Feelings of malaise;
Gastrointestinal problems;
Dizziness;
Headaches;
Problems in the nervous system (feelings of burning, tingling, or numbness of the extremities); and
Cobalt poisoning (skin rashes, cardiomyopathy, problems with hearing, sight or cognition, tremors, and hypothyroidism).